Further, T2DM is associated with changes in the biomarker profile of PD patients, including changes in cerebrospinal fluid tau and serum neurofilament light chain levels, as well as reduced striatal dopamine transporter binding on dopaminergic SPECT imaging. The gene discussed is SLC6A3; the disease is Parkinson disease.